Home / Expertise / Intellectual Property / Patent Opposition and Appeal

Patent Opposition and Appeal

United Kingdom

Granted patents may be opposed by third parties, and our team is often sought out for their advice and representation in post-grant oppositions at the European Patent Office (EPO). We also launch appeal proceedings on behalf of our clients when they have been adversely affected by patent office decisions. A number of our attorneys have been involved in both defending and attacking commercially important patents in multi-party proceedings at the EPO. Often these proceedings have run alongside national litigation proceedings.  We also represent clients at hearings at the UK IPO.

 

Examples of our recent experience:

  • Representing Kymab Limited in opposition of Regeneron’s patents to their platform for antibody discovery (both before the Opposition Division and Appeal Boards), with the proceedings running alongside national litigation. We also represent Kymab in defending patents for their antibody discovery platform and in opposition proceedings relating to CRISPR CAS9 technology.
  • Acting on behalf of Eli Lilly and Company in EPO opposition and appeal proceedings relevant to clearing the way for their migraine biologic.
  • Representing Vectura Group in defending patents relating to inhaled therapeutics, with national litigation running in parallel.
  • Acting for Insmed Incorporated in EPO oppositions relevant to the protection of their phase III asset ALIS.
  • In a further example of managing EPO proceedings alongside national litigation, we represented Silence Therapeutics in opposition proceedings in the field of siRNA therapeutics.
  • Representing a telecoms company in a series of oppositions relating to cellular roaming.
  • Representing Microsoft before the EPO Board of Appeal to appeal Examining Division decisions.
  • Acting on behalf of a medical device manufacturer in oppositions at the EPO.

You can find out more about the specialist technical areas our Patent Attorney team operate in below:

Technology

Life Sciences

Read more Read less